Canaccord lowered the firm’s price target on Pulmonx (LUNG) to $15 from $16 and keeps a Buy rating on the shares. The firm said they reported a relatively in-line first quarter and the company reiterated the 2025 guidance that it already provided. The company is confident that its OUS business in the near term will also not be impacted, expecting continued orders from China.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUNG: